However, despite this, nearly half of such patients still suffer disease relapse due to intrinsic or acquired resistance to the treatments3,4, demonstrating the failure of stratifying breast cancer patients who will benefit from HER2-targeted therapy based solely on HER2 status. This evidence concerns the gene ERBB2 and breast carcinoma.